Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA May Revisit Accelerated Approval For Oncology Products

Executive Summary

FDA's oncology division is interested in revisiting the accelerated approval regulations as they apply to cancer treatments

You may also be interested in...



“Optimal” Dose Finding Could Result In More Late-Stage Drug Success

A paradigm shift from maximum-tolerated dose to effective dose would result in more successful late-stage drug development, FDA Office of Clinical Pharmacology & Biopharmaceutics Pharmacometrics Team Leader Joga Gobburu, PhD, said April 23

“Optimal” Dose Finding Could Result In More Late-Stage Drug Success

A paradigm shift from maximum-tolerated dose to effective dose would result in more successful late-stage drug development, FDA Office of Clinical Pharmacology & Biopharmaceutics Pharmacometrics Team Leader Joga Gobburu, PhD, said April 23

Millennium Velcade Multiple Myeloma Launch Expected In Late 2003

Millennium expects FDA approval of the proteasome inhibitorVelcade for multiple myeloma in the second half of 2003 based on Phase II data

Related Content

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel